Podcast Highlights

What it really takes to launch a GPCR product—years of failure, science, and strategy. Go behind the scenes of pH-Sense with Revity’s Dr. Eric Trinquet.

A powerful new tool tracks GPCR internalization in native cells—no imaging, no overexpression. Learn how pH Sense changes the game for drug discovery.

Ajay Yekkirala’s journey from rejected med student to GPCR biotech founder shows how failure, mentorship, and curiosity can drive real innovation in drug discovery.

Purpose-driven science works because it creates resilience. Careers built on prestige, titles, or external pressure can burn out quickly. But careers built on urgency, alignment, and meaning are the ones that last.

At its core, Catherine Demery’s research is about receptors and signaling pathways—how mu-opioid and alpha-2 adrenergic receptors interact to disrupt breathing. But it’s also about public health urgency.

Catherine Demery shares how walking away from pharmacy school led her to discover a passion for opioid pharmacology. From CRO experience to addiction-focused research, she now investigates fentanyl and xylazine’s effects on respiration using mouse models. Her story offers critical insight into how non-linear paths, personal loss, and public health urgency can shape impactful scientific careers in the GPCR research community.

What does it mean to lead in science as a PhD student? In this episode, Alessandro Nicoli reflects on being the first PhD in a new lab, the challenges of delegating, and the rewards of mentoring students. His story reveals how leadership is learned through shared growth, patience, and shaping the next generation of GPCR researchers. A must-read for scientists balancing research with mentoring responsibilities.

How do you study receptors with no ligands and no structures? In this episode, PhD student Alessandro Nicoli explains how AlphaFold and molecular dynamics are revolutionizing the study of olfactory GPCRs. By turning predictions into starting points, Alessandro and his team are building models that not only match experimental accuracy but also open new doors in ligand discovery, drug design, and the future of computational biology.

From Venice to Munich, follow the story of Alessandro Nicoli, a PhD student whose path into science was anything but linear. In this episode, he shares how a love of chemistry, the guidance of key mentors, and a leap into computational modeling led him to tackle one of biology’s greatest puzzles: olfactory GPCRs. Discover how AlphaFold, molecular dynamics, and curiosity-driven research are reshaping the way we study G protein-coupled receptors.

Should we start research with the model, not the molecule? Dr. Alex Serafini explains how building backwards may be the future of GPCR-driven pain therapy.

Discover how RGS proteins like RGS4 are reshaping our understanding of GPCRs and chronic pain. Dr. Alex Serafini explains the quiet power of GPCR regulation.

Dr. Alex Serafini turned chronic pain into a research mission. Discover how personal experience shaped his work on GPCRs, RGS proteins, and new pain models.

Sokhom Pin explains why staying in GPCR research during its “unpopular” phase helped him become a sought-after expert today.

Sokhom Pin shares how he built a thriving GPCR research team at Alkermes through trust, culture, and empowerment-driven leadership.

Sokhom Pin shares how he earned a PhD while working in biotech, designing a custom program that defied academic convention.

Assay development is more than synthesis. Discover how Celtarys is helping scientists solve GPCR research challenges.

Dr. Maria Majellaro shares the pivotal moments that shaped her career, from chemistry tests to launching a biotech company changing GPCR research.

How Maria Majellaro transitioned from medicinal chemist to biotech CSO, and how Celtarys is now advancing GPCR research tools with Dr. GPCR.

Today’s GPCR researchers want multiplexing, miniaturization, and scale. Here’s the toolkit delivering just that and why it matters now.

Dr. Sakmar reveals how activating GPCR autoantibodies could be driving disease—and how new tools make them detectable.

How one lab’s 30-year GPCR journey became a global resource. Tools, tech, and team science driving GPCR-RAMP discovery.

Ben Clements reflects on pacing, imposter syndrome, and a 10x opioid breakthrough, all powered by curiosity and timing.

Ben Clements shares why fun, mentorship, and community are just as critical as experimental design in GPCR research labs.

A bold new approach to opioid therapy: Ben Clements discusses GPCR-based allosteric modulators and their promise in treating chronic pain without the side effects.